Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned a consensus rating of “Moderate Buy” from the eighteen ratings firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $54.94.

A number of analysts have recently weighed in on NTLA shares. Wells Fargo & Company reduced their target price on shares of Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating on the stock in a research report on Monday, November 18th. Chardan Capital raised their target price on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research note on Monday, November 18th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Robert W. Baird reduced their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Citigroup dropped their target price on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, October 25th.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently made changes to their positions in NTLA. Franklin Resources Inc. increased its holdings in Intellia Therapeutics by 10.3% during the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after buying an additional 1,538 shares during the last quarter. Sanctuary Advisors LLC increased its stake in shares of Intellia Therapeutics by 147.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 53,590 shares of the company’s stock worth $1,101,000 after purchasing an additional 31,976 shares in the last quarter. Virtu Financial LLC purchased a new position in Intellia Therapeutics during the third quarter valued at $417,000. Geode Capital Management LLC grew its holdings in Intellia Therapeutics by 2.2% during the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock valued at $48,164,000 after purchasing an additional 49,367 shares during the period. Finally, Barclays PLC increased its position in Intellia Therapeutics by 17.7% in the third quarter. Barclays PLC now owns 292,795 shares of the company’s stock worth $6,017,000 after buying an additional 44,022 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $12.13 on Friday. Intellia Therapeutics has a fifty-two week low of $11.34 and a fifty-two week high of $34.87. The stock’s 50 day simple moving average is $14.08 and its two-hundred day simple moving average is $19.43. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -2.23 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. The company’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.38) earnings per share. On average, analysts predict that Intellia Therapeutics will post -5.12 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.